Editor’s Note: The following is a summary of one of the talks from the 2013 Nano-bio Symposium hosted by Johns Hopkins Institute for NanoBioTechnology held May 17. This summary was written by Randall Meyer, a doctoral candidate in the biomedical engineering and a member of the Cancer Nanotechnology Training Center. Look for other symposium summaries on the INBT blog.
Nanotechnology bears a multitude of possibilities to systematically and specifically treat many well-characterized and currently untreatable diseases. Despite this, there exist multiple barriers to its development including challenges related to delivery in the human body.
Justin Hanes, a professor of Chemical and Biomolecular Engineering at Johns Hopkins University, highlighted some of the exciting advances that his laboratory has developed to overcoming these challenges. According to Hanes, one of the primary functions of nanobiotechnology is to enable a therapy to be delivered to a specific location and only remain there for as long as it is needed. He likened this idea to applying weed poison to a rose garden. You only want to apply a little bit of poison to a targeted area, not flood the whole garden. Unfortunately conventional cancer chemotherapy is like flooding the garden, but only 1 percent of the drug reaches the tumor. Hanes stated the goal of his work is to flip that so that all but 1 percent of the drug makes it to the site of delivery.
With that in mind, Hanes summarized two stories from his lab of ideas that are successfully being translated from bench to bedside. One therapy involves the use of custom designed nanoparticles that are capable of penetrating the mucus layers of various human tissues to enable a controlled release of drug into the body. The second therapy involves the use of injectable particles to the eye that inhibit blood vessel formation, which is related to diseases such as macular degeneration.
These therapies are being developed by biotech companies launched by Hanes, GrayBug and Kala Pharmaceuticals.